J. Richelcyn M. Baclay

J. Richelcyn M. Baclay

Auto-generated profile, based on publicly available information

J. Richelcyn M. Baclay

Department of Radiation Oncology, Stanford University, Stanford, CA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Practical Radiation Oncology
Verified
Journal Article
Closed access
AKAmanda J. Koong
Amanda J. Koong
DTDiego A.S. Toesca
Diego A.S. Toesca
JBJ. Richelcyn M. Baclay
J. Richelcyn M. Baclay
EPErqi L. Pollom
Erqi L. Pollom
RERie von Eyben
Rie von Eyben
DCDaniel T Chang
Daniel T Chang

1 December 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
EFErin Jay G. Feliciano
Erin Jay G. Feliciano
UJUrvish Jain
Urvish Jain
EDEdward Christopher Dee
Edward Christopher Dee
ASAryan Selokar
Aryan Selokar
JBJ. Richelyn Baclay
J. Richelyn Baclay
NBNirmala Bhoo-Pathy
Nirmala Bhoo-Pathy
PURPOSE: Southeast Asia (SEA), home to over 690 million people across 11 countries—Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor-Leste, and Vietnam—features diverse socioeconomic contexts and cancer care landscapes. We report and interpret incidence and mortality statistics for hematologic malignancies (HMs) in SEA. METHODS: We analyzed 2022 Global Cancer Observatory data from the International Agency for Research on Cancer to report age-standardized incidence rate (ASIR) and age-standardized mortality rates (ASMR) per 100,000 individuals age 20 years and older. We focused on non-Hodgkin lymphoma (NHL), leukemia, multiple myeloma (MM), and Hodgkin lymphoma (HL), standardized using Segi-Doll world population estimates. RESULTS: Across 11 Southeast Asian countries, age-standardized incidence and mortality rates (ASIRs and ASMRs) for HMs vary widely, highlighting significant regional disparities. Singapore consistently reports the highest ASIRs for NHL, leukemia, MM, and HL, yet its ASMRs are much lower, reflecting strong health care infrastructure. Thailand, Brunei, and Malaysia mirror these associations, which are particularly pronounced in NHL and HL. In contrast, for leukemia and MM, Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, the Philippines, Timor-Leste, and Vietnam demonstrated lower ASIR and ASMR that approaches ASIR, suggesting barriers to diagnosis and survivorship. Time trends suggest increasing mortality from MM and NHL, particularly in Thailand and the Philippines. Overall, survival outcomes correlate strongly with national health care capacity. CONCLUSION: Higher reported incidence in wealthier SEA countries may reflect greater diagnostic capacity, whereas similar incidence and mortality in low-income countries likely indicates limited access to timely diagnosis and treatment. Mortality patterns underscore the region's broad disparities in cancer care infrastructure and outcomes, shaped by socioeconomic and systemic health inequities.

29 November 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
RKRitesh Kumar
Ritesh Kumar
CHChris L Hallemeier
Chris L Hallemeier
DCDaniel T Chang
Daniel T Chang
SLShou-En Lu
Shou-En Lu
LHLara Hathout
Lara Hathout
SJSalma Jabbour
Salma Jabbour
Anal squamous cell carcinoma (ASCC) is a rare cancer with increased occurrence of multiple cancers before and after the ASCC diagnosis. However, there is limited data on this aspect. This multi-institutional analysis aimed to define the occurrence of malignancies before and after ASCC, time trends, impact on survival, and identify prognostic factors. Initial primary malignancy (IPM) was defined as a malignancy occurring before the ASCC. Second primary malignancy (SPM) was defined as a distinct primary cancer that developed after ASCC diagnosis. Retrospective multi-institutional chart review was done. Progression free survival (PFS), overall survival (OS) and prognostic factors were evaluated. 647 patients with ASCC treated with curative intent were analyzed. Median age was 61.23 years with 72% as females. 150 patients (23.3%) had multiple malignancies with IPM in 16% and SPM in 8%. Patients without prior cancer had better 5-year PFS (81.2% vs 67.2%, p = .011) and OS (81% vs 69%, p = .008) compared to those with prior cancer. SPMs had a significant adverse impact on PFS (HR 4.22) and OS (HR 3.56). Females had better 5-year PFS (82% vs 70%, p = .016) as compared to males. The median time interval for developing ASCC (as SPM) after IPM was 9.32 years. ASCC patients have increased risk of multiple malignancies. Patients with prior cancer have inferior outcomes. SPM is a poor prognostic factor in patients without any prior cancer. SPM can develop years after treatment of primary ASCC.